Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation

Brief Description Of Study

The GLORIA-AF Registry Program consists of three phases and is an observational study. It is designed to characterize newly diagnosed patients with non-valvular atrial fibrillation at risk for stroke in different regions of the world and to describe current patterns of antithrombotic treatments selected at the patients baseline visit. The baseline visit of each phase is defined as the visit in which the patient is enrolled into the registry. In addition, safety data and outcomes of such patients will be collected in Phase II and III of the Registry program. Phase I is described in a separate protocol and is only related to the pre-approval time. The present protocol describes the combined Phase II and III of the GLORIA-AF Registry Program. In each phase newly diagnosed non-valvular AF patients at risk of stroke, as characterized by a CHA2DS2-VASc score of at least 1 are planned to be included. This is an observational study, which means it is a study that does not prescribe specific medication or require procedures outside of usual medical care.

Clinical Study Identifier: 816873

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.